不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein.
Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
据估计,全球有1000万至2000万人感染了δ逆转录病毒人T细胞白血病病毒1型(HTLV-1)。尽管大多数感染者保持无症状,但部分人会进展为致命且使人衰弱的疾病——成人T细胞白血病/淋巴瘤(ATLL)或HTLV相关脊髓病/热带痉挛性截瘫(HAM/TSP),或发展为大量其他炎症性疾病。
此外,HTLV-1感染与免疫抑制和寿命缩短相关。尽管中和抗体的保护作用已被提出,但非中和性抗体依赖性细胞介导的细胞毒性(ADCC)的作用仍不清楚,主要因为尚未建立检测这种反应的试验方法。
在此,我们开发了一种基于高通量流式细胞术的检测系统,用于测量HTLV-1包膜特异性ADCC。我们使用稳定表达绿色荧光蛋白GFP的NK 细胞抗性T淋巴母细胞样细胞系,构建了表达HTLV-1包膜蛋白的靶细胞系,并使用单克隆抗体以及来自HTLV感染或未感染个体的血浆样本,验证了该试验的特异性和敏感性。
我们在HTLV-1感染人类的样本中检测到高ADCC活性。在实验感染猕猴的血浆中,测量了ADCC活性,并观察到ADCC活性与HTLV-1包膜抗体滴度之间的相关性。
此外,我们观察到ADCC滴度随时间显著增加;随着HTLV-1感染的持续,产生更高的ADCC反应,可能影响疾病结局。HTLV-1感染猕猴中的ADCC滴度也与FLT3LG、IL-17F、CD4+ T细胞和淋巴细胞呈正相关,但与单核细胞频率和经典单核细胞频率呈负相关。
总之,这些发现详细描述了一个细胞系的建立,该细胞系使得HTLV特异性ADCC检测方法的开发成为可能,该方法可用于大型临床研究以及涉及人类或非人灵长类动物的研究。重要性 该方法测量人类T细胞白血病病毒(HTLV)特异性包膜抗体依赖性细胞介导的细胞毒性反应,为研究包膜特异性结合抗体在HTLV感染免疫控制和发病机制中的作用提供了关键工具,并可能有助于指导治疗性和预防性疫苗方法的开发。
An estimated 10-20 million people worldwide are infected with the deltaretrovirus human T-cell leukemia virus type 1 (HTLV-1). Although most infected individuals remain asymptomatic, some progress to develop the fatal and debilitating disease adult T-cell leukemia/lymphoma (ATLL) or HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) or develop a plethora of other inflammatory disorders.
In addition, HTLV-1 infection is associated with immunosuppression and a shorter lifespan. Although a protective role for neutralizing antibodies has been suggested, the role of non-neutralizing antibody-dependent cell-mediated cytotoxicity (ADCC) remains unclear, largely because an assay to measure this response has not been established.
Here, we developed a high-throughput flow cytometry-based assay system to measure HTLV-1 envelope-specific ADCC.
We used a natural killer cell-resistant T-lymphoblastoid cell line stably expressing the green fluorescent protein GFP to construct a target cell line expressing HTLV-1 envelope protein and using monoclonal antibodies and plasma samples from HTLV-infected or uninfected individuals, validating the specificity and sensitivity of the assay.
We detected high ADCC activity in samples from HTLV-1-infected humans. In the plasma of experimentally infected macaques, ADCC activity was measured and a correlation between ADCC activity and HTLV-1 envelope antibody titers was observed.
Further, we observed a significant increase in ADCC titer over time; as HTLV-1 infection persists, a higher ADCC response is generated, potentially influencing disease outcome. ADCC titer in HTLV-1-infected macaques also positively correlated with FLT3LG, IL-17F, CD4 + T cells, and lymphocytes but negatively correlated with monocyte frequency and classical monocyte frequency.
In conclusion, these findings detail the generation of a cell line that enabled development of an HTLV-specific ADCC assay, which can be employed in large clinical studies as well as research involving humans or non-human primates.
IMPORTANCEThis approach measures human T-cell leukemia virus (HTLV)-specific envelope antibody-dependent cell-mediated cytotoxicity responses, provides a critical tool to investigate the role of envelope-specific binding antibodies in the immune control of HTLV infection and pathogenesis, and may help guide the development of both therapeutic and preventative vaccine approaches.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。